Total Long Term Debt (Quarterly) Chart

View Total Long Term Debt (Quarterly) for NRIX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Total Long Term Debt (Quarterly) Chart
Start Trial

Historical Total Long Term Debt (Quarterly) Data

View and export this data back to 2019. Start Trial.
Date Value
May 31, 2026 54.92M
February 28, 2026 55.45M
November 30, 2025 52.91M
August 31, 2025 52.70M
May 31, 2025 46.70M
February 28, 2025 19.98M
November 30, 2024 20.29M
August 31, 2024 20.59M
May 31, 2024 20.88M
February 29, 2024 21.85M
November 30, 2023 23.12M
August 31, 2023 2.642M
May 31, 2023 3.758M
February 28, 2023 5.106M
November 30, 2022 6.434M
Date Value
August 31, 2022 7.745M
May 31, 2022 9.043M
February 28, 2022 10.33M
November 30, 2021 9.189M
August 31, 2021 0.00
May 31, 2021 0.00
February 28, 2021 0.00
November 30, 2020 0.00
August 31, 2020 0.00
May 31, 2020 168.11M
February 29, 2020 48.20M
November 30, 2019 0.00
August 31, 2019 0.00
May 31, 2019 0.00
February 28, 2019 0.00

Total Long Term Debt Definition

Represents a company's total debt maturing for more than 12 months of the reporting period.

Read full definition.

Total Long Term Debt (Quarterly) Range, Past 5 Years

View Total Long Term Debt (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Total Long Term Debt (Quarterly) Benchmarks

View Total Long Term Debt (Quarterly) Benchmarks
Start Trial
Monte Rosa Therapeutics, Inc. 33.36M
Gilead Sciences, Inc. 26.25B
TG Therapeutics, Inc. 752.53M
Cue Biopharma, Inc. 7.179M
Keros Therapeutics, Inc. 13.13M